Real-life experience with chlormethine gel for early-stage mycosis fungoides with emphasis on types and management of cutaneous side-effects#

2021 ◽  
pp. 1-7
Author(s):  
Hadas Prag Naveh ◽  
Iris Amitay-Laish ◽  
Omri Zidan ◽  
Yael A. Leshem ◽  
Shany Sherman ◽  
...  
Keyword(s):  
Side Effects ◽  
Mycosis Fungoides ◽  
Life Experience ◽  
Early Stage ◽  
Real Life ◽  
Cutaneous Side Effects

Vascular toxicities of endocrine therapy in early-stage breast cancer: Encouraging observations in a nontrial setting.

2012 ◽  
Vol 30 (27_suppl) ◽  
pp. 68-68
Author(s):  
Susan Faye Dent ◽  
Freya L. Crawley ◽  
Nadine A. Graham ◽  
Michelle M. Campbell
Keyword(s):  
Breast Cancer ◽  
Endocrine Therapy ◽  
Life Experience ◽  
Early Stage ◽  
Real Life ◽  
Standard Of Care ◽  
T Test ◽  
Early Stage Breast Cancer ◽  
Cancer Center ◽  
Increased Risk

68 Background: Endocrine therapy (ET) is the standard of care for postmenopausal (PM) women with early stage breast cancer (EBC). Studies suggest higher risk of vascular toxicities (VT) on aromatase inhibitor (AI) therapy. We report incidence/discontinuation rates of VTs in a cardiac clinic. Methods: PM women with hormone receptor positive EBC treated with ET (tamoxifen (T) ± AI) at Ottawa Hospital Cancer Center 01/99-2/06. Data included: demographics, vascular co-morbidities (VCM), ET, duration, VTs. Results: 626 pts, median age 59 years (r: 30-92), median follow-up 98 months (m), stage: I (196 pts), II (341 pts) III (89 pts) EBC. Majority (52.5%) pts had VCM at ET initiation; hypertension (HTN) (36%), hyperlipidemia (HYLP) (17%), coronary disease (12%), thrombosis (9%), angina (6%) TIA (6%). Treatment discontinued due to VT 3x more with T vs. AI. Most common VTs: edema, arrhythmias (ARR), cardiovascular (CVS) event, and HYLP. With Letrozole and T, previous VCM significantly increased risk of developing VT (chi-square: P=0.022 and 0.009). Time to develop VT shortest for T and exemestane. Previous VCM did not affect this interval. Longer exposure to T correlated with higher VT rate (t-test: p=0.046) not seen with AIs. Exposure to multiple AIs associated with higher VT rate (t-test: p=0.009). Conclusions: This cohort study reports similar VT rates with AI therapy as reported in the literature. T was associated with higher discontinuation rates (10.5%) due to VTs compared to AIs (2.8-3.3%). Longer duration of AI therapy was not associated with increased risk of VTs. These encouraging results reflect the real-life experience of women exposed to ET. [Table: see text]

W1206 Side-Effects to Adalimumab – Single Center Real Life Experience in 111 Crohn's Disease Patients

2010 ◽  
Vol 138 (5) ◽  
pp. S-674
Author(s):  
Zuzana Zelinkova ◽  
Rachel L. West ◽  
Evelien Bultman ◽  
Astrid van Liere-Baron ◽  
Peter Mensink ◽  
...  
Keyword(s):  
Crohn’S Disease ◽  
Side Effects ◽  
Crohn's Disease ◽  
Life Experience ◽  
Real Life ◽  
Single Center

scholarly journals Analogs in the treatment of chronic hepatitis B: real life experience with tenofovir and entecavir

2015 ◽  
Vol 9 (2) ◽  
pp. 57-62
Author(s):  
Rosanna Villani ◽  
Roberta Forlano ◽  
Gianluigi Vendemiale ◽  
Gaetano Serviddio
Keyword(s):  
Chronic Hepatitis ◽  
Side Effects ◽  
Hepatitis B ◽  
Serum Creatinine ◽  
Viral Replication ◽  
Creatinine Clearance ◽  
Chronic Hepatitis B ◽  
Life Experience ◽  
Real Life ◽  
High Serum

INTRODUCTION: Tenofovir and entecavir are potent antiviral agents. By suppressing viral replication, they induce histological improvement and finally delay the progression of chronic hepatitis B and the development of complications. They are rarely associated with serious side effects. Our data from a real life experience support data from the literature and suggest some minimal difference that may be useful in tailoring therapy.PATIENTS AND METHODS: We retrospectively analyzed 54 patients affected by chronic hepatitis B (31 and 23 treated by entecavir and tenofovir, respectively). Eight patients were cirrhotic. At baseline and 4-12 and 24 weeks after starting therapy, biochemical and virological analysis were performed in all patients. Renal function tests (serum creatinine, creatinine clearance and blood urea), serum (calcium and phosphate blood level) and urine electrolyte were also studied.RESULTS: All the patients reached virological control within 24 weeks. Only in the group treated by tenofovir we observed a complete viral suppression within 12 weeks. Some patients treated with tenofovir showed increased creatinine clearance without serum creatinine alteration. No significant side effects were reported with the exception of one case of persistent headache in the entecavir group for which the drug was suspended.CONCLUSIONS: Entecavir and tenofovir are effective in suppressing viral replication in patients with chronic hepatitis B. Tenofovir is more potent than entecavir and viral replication is blocked within 12 weeks of therapy. Tenofovir administration is associated with slight increase of creatinine clearance without alteration of serum creatinine levels. The choice of one or the other should be made according to target and specific patients characteristics. In patients with high serum viral load where the complete and quick control of viral replication is the main target, tenofovir may represent the best choice.

Effectiveness and side effects of thiazolidinediones for type 2 diabetes: real‐life experience from a tertiary hospital

2004 ◽  
Vol 181 (10) ◽  
pp. 536-539 ◽  
Author(s):  
Zanariah Hussein ◽  
John M Wentworth ◽  
Alison J Nankervis ◽  
Joseph Proietto ◽  
Peter G Colman
Keyword(s):  
Type 2 Diabetes ◽  
Side Effects ◽  
Life Experience ◽  
Real Life ◽  
Tertiary Hospital

scholarly journals Combination of rRT-PCR and Anti-Nucleocapsid/Anti-Spike Antibodies to Characterize Specimens with Very Low Viral SARs-CoV-2 Load: A Real-Life Experience

2021 ◽  
Vol 9 (6) ◽  
pp. 1263
Author(s):  
Zoe Florou ◽  
Meropi Zigra ◽  
Philippos Kartalidis ◽  
Katerina Tsilipounidaki ◽  
Georgia Papadamou ◽  
...  
Keyword(s):  
Viral Load ◽  
Life Experience ◽  
Early Stage ◽  
Real Life ◽  
Serum Specimen ◽  
Chain Reaction ◽  
Serum Samples ◽  
Viral Loads ◽  
Polymerase Chain ◽  
Positive Results

The objective of the present study was to evaluate the true positivity among people, whose results of initial testing of nasopharyngeal swabs (NPS) showed a very low viral load of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Seventy-seven people detected with low viral loads of SARs-CoV-2 in nasopharyngeal samples (Ct ≥ 35) were enrolled in the study. For this purpose, a second NPS was collected for rRT-PCR (real-time reverse transcription polymerase chain reaction) combined with a pair of serum samples for detection of anti-nucleocapsid (anti-N) and anti-spike (anti-S) antibodies. In 8 people, subsequent examinations indicated an increase in viral loads, thereafter, followed by an increase of anti-N and anti-S antibodies, findings compatible with an early stage of COVID-19 infection. In 9 people, who already had increased anti-N antibodies, subsequent examination showed a decrease or absence of viral load and an increase in antibodies, indicative of a late stage of COVID-19 infection. In 60 people, subsequent examination showed absence of infection (as indicated by absence of viral load and antibodies). We propose that the combination of a second NPS and one serum-specimen, both taken three days after the first NPS, helps significantly to avoid false-positive results.

scholarly journals Toxicities Associated with Docetaxel-Based Regimens in the Adjuvant Treatment of Early-Stage Breast Cancer: A Multicenter Prospective Real-Life Experience

Breast Care ◽  
2018 ◽  
Vol 13 (2) ◽  
pp. 119-123
Author(s):  
Elie El Rassy ◽  
Marwan Ghosn ◽  
Fadi Farhat ◽  
Ziad Bakouny ◽  
Tarek Assi ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Adverse Events ◽  
Cancer Patients ◽  
Life Experience ◽  
Early Stage ◽  
Real Life ◽  
Early Stage Breast Cancer ◽  
Efficacy And Safety ◽  
Breast Cancer Patients ◽  
Skin Reactions

Background: The present study reports on the efficacy and safety of adjuvant docetaxel in real-life patients with early-stage breast cancer. Methods: This is a prospective, multicenter, post-marketing study that evaluates the efficacy and safety of docetaxel-based regimens in patients with early breast cancer treated between 2007 and 2012. Results: A total of 698 female breast cancer patients receiving adjuvant docetaxel-based regimens were included in this study. Docetaxel monotherapy was administered in 4.2%, whilst most patients received polychemotherapy. Non-hematological adverse events included skin reactions in 32.7% of the subjects. Multiple adverse events were reported and most commonly included asthenia (66.5%), alopecia (43.4%), and diarrhea (24.2%). It is noteworthy that no fatal toxicities occurred. Several hematological adverse events were reported during treatment, with anemia being the most common. Conclusion: The results of this real-life experience, characterized by a relatively large sample size and long follow-up, confirm that docetaxel is effective and well tolerated in early-stage breast cancer patients.

Implementing NGS-based BRCA tumour tissue testing in FFPE ovarian carcinoma specimens: hints from a real-life experience within the framework of expert recommendations

2020 ◽  
pp. jclinpath-2020-206840
Author(s):  
Daniela Rivera ◽  
Michele Paudice ◽  
Viviana Gismondi ◽  
Giorgia Anselmi ◽  
Valerio Gaetano Vellone ◽  
...  
Keyword(s):  
Life Experience ◽  
Early Stage ◽  
Real Life ◽  
Copy Number Variations ◽  
Tumour Tissue ◽  
Consecutive Series ◽  
Cell Content ◽  
Pathogenic Variants ◽  
Formalin Fixed Paraffin Embedded ◽  
Expert Recommendations

AimsNext Generation Sequencing (NGS)-based BRCA tumour tissue testing poses several challenges. As a first step of its implementation within a regional health service network, an in-house validation study was compared with published recommendations.MethodsEpithelial ovarian cancer (EOC) formalin-fixed paraffin-embedded specimens stored in the archives of the eight regional pathology units were selected from a consecutive series of patients with known BRCA germline status. Two expert pathologists evaluated tumour cell content for manual macrodissection. DNA extraction, library preparation and NGS analyses were performed blinded to the germinal status. Parameters used in the study were confronted with guidelines for the validation of NGS-based oncology panels and for BRCA tumour tissue testing.ResultsNGS analyses were successful in 66 of 67 EOC specimens, with good quality metrics and high reproducibility among different runs. In all, 19 BRCA pathogenic variants were identified: 12 were germline and 7 were somatic. A 100% concordance with blood tests was detected for germline variants. A BRCA1 variant showed a controversial classification. In different areas of two early stage EOCs showing somatic variants, intratumour heterogeneity not relevant for test results (variant allele frequency >5%) was observed. Compared with expert recommendations, main limitations of the study were absence of controls with known somatic BRCA status and exclusion from the validation of BRCA copy number variations (CNV).ConclusionsA close collaboration between pathology and genetics units provides advantages in the implementation of BRCA tumour tissue testing. The development of tools for designing and interpreting complex testing in-house validation could improve process quality.

Sign in / Sign up

Export Citation Format

Share Document